A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 188 participants.

Also called NCT03496623

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 188 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03496623
Other papers using this trial's data
  • Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results The European respiratory journal, 2024-06 DOI, PubMed 38811045, PMC11154754 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Israel, Puerto Rico (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03496623. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-08 (actual); primary completion 2022-10-13 (actual). Results posted on 2023-11-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
Acronym
PERFECT
Condition
Chronic Obstructive Pulmonary Disease
Intervention (Drug)
Inhaled treprostinil solution
Intervention (Drug)
Placebo solution
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03496623
Content hash
82f889d9249d0aae6e42851e796ba34f9e36fd7c3a90efa6aeef1fc6f55908b4